A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Clinical Trial ID NCT01959529

PubWeight™ 9.82^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01959529

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	A review of the pharmacological properties of insulin degludec and their clinical relevance.	Clin Pharmacokinet	2014	1.16
2	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.	Diabetes Metab Syndr Obes	2014	1.05
3	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.	Circulation	2016	0.84
4	Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.	Diabetes Ther	2016	0.79
5	Current perspectives on cardiovascular outcome trials in diabetes.	Cardiovasc Diabetol	2016	0.79
6	Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan.	J Diabetes Investig	2015	0.75
7	Cardiovascular effects of basal insulins.	Drug Healthc Patient Saf	2015	0.75
8	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.	Clin Pharmacol Ther	2015	0.75
9	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).	Appl Health Econ Health Policy	2019	0.75
10	Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.	Cardiovasc Diabetol	2016	0.75
11	Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.	Expert Rev Endocrinol Metab	2015	0.75
12	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.	Herz	2016	0.75
13	Concentrated insulins: the new basal insulins.	Ther Clin Risk Manag	2016	0.75